Point-of-care biosensors market valued at £25 billion by 2027

Point-of-care biosensors will grow to be a £25 billion market by 2027 forecasts IDTechEx Research
.

The firm predicts that point-of-care (PoC) biosensors will become a £25 billion market by 2027, with molecular diagnostic devices the main driver for this growth. The group’s report gives a complete analysis of the important trends in the field of medical biosensors, and lists the new technologies and devices which are likely to be highly disruptive to the in-vitro diagnostics market.

Biosensors are used to detect and quantify biological material associated with a disease state or health condition (biomarkers), making them powerful tools for diagnosis and monitoring. As technological advances allow for such tests to be conducted faster and on smaller devices, these tests are moving out of specialised laboratories and closer to the patient at the point-of-care.


In this analysis of the market, 'point-of-care' is defined as being portable and able to gives results in under one hour. Commercial biosensors are split in four categories: lateral flow assays; electrochemical test strips; integrated cartridges; and molecular diagnostics.

In addition, the report gives a ten-year market forecast segmented by application, including infectious disease self-monitoring, glucose testing, cancer, cardiometabolic, pregnancy & fertility and genetic testing.

The group says that the report, Biosensors for Point-of-Care Testing: Technologies, Applications, Forecasts 2017-2027 will be useful to any company wishing to be in the value chain of biosensors (materials suppliers, reagent suppliers, microfluidics, contract manufacturers, foundries).

The two authors of the report, Dr Laura Baers and Dr David Pugh, will be presenting their analysis on PoC biosensors at the upcoming Business and Technologies Insight Forums hosted by IDTechEx in Seoul (19-21 September) and Tokyo (27-29 September).